+57.7%
GSK vs GTLB
-47.1%
+104.9%
-37.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GTLB | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.1% | -3.0% | -1.9% |
| 7D | -1.8% | +11.1% | -12.9% | -2.1% |
| 30D | -2.2% | +37.8% | -40.0% | -2.9% |
| 3M | -1.8% | +61.6% | -63.4% | -2.9% |
| 6M | -10.6% | +98.9% | -109.5% | -12.2% |
| YTD | +4.4% | +32.8% | -28.3% | +3.7% |
| 1Y | +30.4% | +14.7% | +15.8% | +29.9% |
| 3Y | +60.1% | +1.3% | +58.7% | +58.3% |
| All | +57.7% | -47.1% | +104.9% | +52.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GTLB.
Daily Out/Under-Performance
Portfolio return minus GTLB return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GTLB return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GTLB wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling